Francisco Aya

Barcelona, CT 08036, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Personalized Circulating Tumor DNA Assay to Assess Long-Term Clinical Benefit in Patients with Advanced Melanoma.

Personalized Circulating Tumor DNA Assay to Assess Long-Term Clinical Benefit in Patients with Advanced Melanoma.

Journal: Cancers

Published: October 16, 2025

Assessing brain metastasis response to immunotherapy: a pictorial review of atypical responses and intracranial adverse events.

Assessing brain metastasis response to immunotherapy: a pictorial review of atypical responses and intracranial adverse events.

Journal: Insights into imaging

Published: June 08, 2025

Pembrolizumab therapy leads to resolution of lentigines and tumour control in a patient with xeroderma pigmentosum and advanced cutaneous squamous cell carcinoma.

Pembrolizumab therapy leads to resolution of lentigines and tumour control in a patient with xeroderma pigmentosum and advanced cutaneous squamous cell carcinoma.

Journal: Clinical and experimental dermatology

Published: April 01, 2025

Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma.

Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma.

Journal: International journal of molecular sciences

Published: November 21, 2024

Adjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of Relapse.

Adjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of Relapse.

Journal: Cancers

Published: November 20, 2024

Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist's Perspective on Current Knowledge.

Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist's Perspective on Current Knowledge.

Journal: International journal of molecular sciences

Published: July 17, 2024

Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy.

Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 02, 2024

Predictive and Prognostic Factors in Melanoma Central Nervous System Metastases-A Cohort Study.

Predictive and Prognostic Factors in Melanoma Central Nervous System Metastases-A Cohort Study.

Journal: Cancers

Published: May 17, 2024

Shaping human brain development and vulnerability through alternative splicing.

Shaping human brain development and vulnerability through alternative splicing.

Journal: Cell genomics

Published: May 15, 2024

Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.

Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 25, 2024

Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanoma.

Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanoma.

Journal: Cell reports

Published: August 29, 2023

Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival.

Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival.

Journal: Cancers

Published: January 14, 2022

Showing 1-12 of 25

Last Updated: 09/26/2026